The Pharmacoeconomics of deep vein thrombosis treatment

Venous thromboembolism ( VTE), encompassing both deep vein thrombosis ( DVT) and pulmonary embolism, remains a common and costly condition that is associated with significant morbidity and mortality. Treatment options for initial management of DVT include unfractionated heparin ( UFH), low- molecular- weight heparins ( LMWHs), and fondaparinux, which is the first of a new class of pentasaccharide antithrombotic agents with anti - factor Xa activity. LMWHs are an important tool in DVT management, offering advantages over UFH such as ease of dosing, lack of need for coagulation monitoring, and reduced risk for heparin- induced thrombocytopenia ( HIT). Fondaparinux is also characterized by a simple dosing regimen, no need for coagulation monitoring, and potentially a lower risk of HIT compared with LMWH. In a recent clinical trial of DVT management, efficacy and bleeding rates with fondaparinux appeared similar to those observed with LMWH. In contrast to LMWH, fondaparinux is generally given as a fixed dose across a range of patient weights rather than calculated per individual patient weight. Given the increasing economic burden of VTE, particularly due to its increased rate among the elderly, pharmacoeconomic analyses have become a particularly useful tool to aid in selecting among similarly effective and safe agents for VTE treatment. A recent cost- effective analysis demonstrated that fondaparinux use offers an attractive economic alternative to other agents for initial DVT therapy that could yield cost savings without compromising clinical outcomes or patient safety. (C) 2007 Elsevier Inc. All rights reserved.